Compare Asmacure vs Threshold Pharmaceuticals
Customers evaluate the quality of Asmacure's products using the following success metrics.
Overview
Asmacure is 22 yrs old and is based in Canada.
Asmacure is a biotechnology company that develops therapeutics for the treatment of asthma. It involves in the development of a patented drug targeting the treatment of inflammatory diseases, particularly with reference to the lung. The company's products include ASM-002, which is a generic agonist of nicotinic receptors.
Threshold Pharmaceuticals is 23 yrs old and is based in United States.
Threshold Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor and certain other diseased cells, Threshold's pipeline of drug candidates holds promise to be more effective and less toxic to healthy tissues than conventional drugs. Threshold's initial clinical focus is the treatment of cancer and benign prostatic hyperplasia, or BPH, a disease afflicting tens of millions of men worldwide.
Demo Video
Leadership
Luc Vachon (President)
George F. Tidmarsh (Founder)
Investors
Odan Laboratories, Innovatech Quebec
Molecular Templates, Three Arch Partners
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Asmacure has not claimed their profile.
Work for Asmacure? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Asmacure?
Claim your profile now.
Information not available because Threshold Pharmaceuticals has not claimed their profile.
Work for Threshold Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Threshold Pharmaceuticals?
Claim your profile now.